Roxadustat treatment for anemia in patients undergoing long-term dialysis

New England Journal of Medicine

Volumn 381, Issue 11, 2019, Pages 1011-1022

  Chen, Nan ^a   Hao, Chuanming ^b   Liu, Bi Cheng ^c   Lin, Hongli ^f   Wang, Caili ^g   Xing, Changying ^d   Liang, Xinling ^h   Jiang, Gengru ^a   Liu, Zhengrong ⁱ   Li, Xuemei ^j   Zuo, Li ^k   Luo, Laimin ⁿ   Wang, Jianqin ^o   Zhao, Ming Hui ^l   Liu, Zhihong ^e   Cai, Guang Yan ^m   Hao, Li ^p   Leong, Robert ^q   Wang, Chunrong ^q   Liu, Cameron ^q   Neff, Thomas ^q   Szczech, Lynda ^q   Yu, Kin Hung P ^q   more..

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e NANJING UNIVERSITY   (China)

^f DALIAN MEDICAL UNIVERSITY   (China)

^g INNER MONGOLIA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

ⁱ SOUTHERN MEDICAL UNIVERSITY   (China)

^j PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^k PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^l PEKING UNIVERSITY   (China)

^m CHINESE PLA GENERAL HOSPITAL   (China)

ⁿ NANCHANG UNIVERSITY   (China)

^o LANZHOU UNIVERSITY   (China)

^p ANHUI MEDICAL UNIVERSITY   (China)

^q FibroGen   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFEPOETIN ALFA; HEMOGLOBIN; HEPCIDIN; IRON; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROXADUSTAT; TRANSFERRIN; ANTIANEMIC AGENT; CHOLESTEROL; FG-4592; GLYCINE; HYPOXIA INDUCIBLE FACTOR PROLINE DIOXYGENASE; ISOQUINOLINE DERIVATIVE; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; IRON BLOOD LEVEL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; TRANSFERRIN BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; AGED; ANALYSIS OF VARIANCE; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; DOUBLE BLIND PROCEDURE; HEMODIALYSIS; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANEMIA; CHOLESTEROL; DOUBLE-BLIND METHOD; EPOETIN ALFA; FEMALE; GLYCINE; HEMATINICS; HEMOGLOBINS; HUMANS; HYPERKALEMIA; HYPERTENSION; HYPOXIA-INDUCIBLE FACTOR-PROLINE DIOXYGENASES; ISOQUINOLINES; MALE; MIDDLE AGED; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 85072278721     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1901713     Document Type: Article

References (38)

1. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One 2014;9(1):e84943.
2. Smith RE Jr. The clinical and economic burden of anemia. Am J Manag Care 2010;16:Suppl:S59-S66.
3. Nakhoul G, Simon JF. Anemia of chronic kidney disease: treat it, but not too aggressively. Cleve Clin J Med 2016; 83:613-24.
4. Hörl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301.
5. KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:Suppl 3:S11-S145.
6. Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:Suppl 2:1-ii47.
7. Kliger AS, Foley RN, Goldfarb DS, et al. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis 2013;62: 849-59.
8. Anaemia management in chronic kidney disease: clinical guideline: methods, evidence and recommendations. London: National Clinical Guidelines Centre, June 2015 (https://www.nice.org.uk/guidance/ng8/evidence/full-guideline-pdf-70545136).
9. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584-90.
10. Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146-55.
11. Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008;74: 791-8.
12. Li YB, Wang M. The challenge and measures after dialysis therapy entered in rural medical insurance of serious diseases. Chinese Health Economics 2013; 10:12-4.
13. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol 2012;23: 1631-4.
14. Bernhardt WM, Wiesener MS, Scigalla P, et al. Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD. J Am Soc Nephrol 2010;21:2151-6.
15. Semenza GL, Agani F, Booth G, et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int 1997; 51:553-5.
16. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 2008;7:28-32.
17. Nangaku M, Kojima I, Tanaka T, Ohse T, Kato H, Fujita T. Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase. Recent Pat Cardiovasc Drug Discov 2006;1:129-39.
18. Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 2016;67:912-24.
19. Provenzano R, Besarab A, Sun CH, et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol 2016; 11:982-91.
20. Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant 2015;30:1665-73.
21. Yu KH, Chou J, Klaus S, et al. Comparable doses of FG-4592 have similar PK/PD in healthy Caucasian and Japanese subjects. Nephrol Dial Transplant 2013;28: Suppl 1:i362. abstract.
22. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510-4.
23. Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998;8:588-94.
24. Chen N, Qian J, Chen J, et al. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant 2017;32:1373-86.
25. Center of Drug Evaluation (CFDA). Announcement on issuance of guidelines on biostatistics of drug clinical trials (no.
26. 93, 2016). June 2016. (In Chinese) (http://www.cde.org.cn/zdyz.do?method=largePage&id=272).
27. Mauri L, D'Agostino RB Sr. Challenges in the design and interpretation of noninferiority trials. N Engl J Med 2017;377: 1357-67.
28. Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med 2013;368:307-19.
29. Schafer JL. Analysis of incomplete multivariate data. London: Chapman & Hall, 1997.
30. Barnard J, Rubin DB. Small-sample degrees of freedom with multiple imputation. Biometrika 1999;86:948-55.
31. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213-26.
32. Gomes AC, Gomes MS. Hematopoietic niches, erythropoiesis and anemia of chronic infection. Exp Hematol 2016;44: 85-91.
33. Bradbury BD, Critchlow CW, Weir MR, Stewart R, Krishnan M, Hakim RH. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients. Nephrol Dial Transplant 2009;24:919-25.
34. Szczech LA, Besarab A, Saikali KG, et al. Roxadustat treatment of CKD anemia is not influenced by inflammation. Presented at the American Society of Nephrology Annual Scientific Meeting, Kidney Week 2017, New Orleans, October 31-Novem-ber 5, 2017 (https://www.asn-online.org/education/kidneyweek/2017/program -abstract.aspx?controlId=2772486).
35. Besarab A, Chernyavskaya E, Motylev I, et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol 2016;27:1225-33.
36. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-9.
37. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586.
38. Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 2019;381:1001-10.